预约演示
更新于：2025-05-28
Emtricitabine/Tenofovir Disoproxil Fumarate
恩曲他滨替诺福韦
更新于：2025-05-28
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-08-02), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C31H44FN8O17PS |
InChIKeyVERWQPYQDXWOGT-LVJNJWHOSA-N |
CAS号731772-45-5 |
关联
228
项与 恩曲他滨替诺福韦 相关的临床试验NCT06816043
An Open-label, Phase 1 Study to Characterize the Effects of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) on the Pharmacokinetics of MK-8527 in Healthy Participants
NCT06560684
A PHASE 2 CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR-BASED PREP EVALUATING EXTENDED SAFETY, ACCEPTABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS
NCT06513312
A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Persistence, Safety, Acceptability, and Pharmacokinetics of Twice Yearly Long-acting Subcutaneous Lenacapavir for HIV Pre-Exposure Prophylaxis (PrEP) in People Who Would Benefit From PrEP
100 项与 恩曲他滨替诺福韦 相关的临床结果
登录后查看更多信息
100 项与 恩曲他滨替诺福韦 相关的转化医学
登录后查看更多信息
100 项与 恩曲他滨替诺福韦 相关的专利（医药）
登录后查看更多信息
453
项与 恩曲他滨替诺福韦 相关的文献（医药）2025-04-01Therapeutic Advances in Infectious Disease
Exploring pregnant women’s experiences with dapivirine vaginal ring insertion during the MTN-042/DELIVER study in Uganda: a description of secondary data
Article
作者: Ssemambo, Phionah Kibalama ; Nalwoga, Justine ; Ssekasi, Annette Miwanda ; Mirembe, Brenda Gati ; Nakabiito, Clemensia ; Nansimbe, Joselyne ; Byogero, Rose
Background::
Involving pregnant women in HIV prevention trials is key to ensuring that they benefit from efficacious products. MTN-042/DELIVER was a phase IIIb, open-label, multi-site, randomized safety study, the first of its kind to enroll HIV-negative pregnant women into a prevention trial using oral Truvada
®
once daily and the Dapivirine Vaginal Ring (DVR) every month. There is limited data on pregnant women’s experiences with ring insertion, which we explored.
Objectives::
To explore the experiences of pregnant women with DVR insertion during the MTN-042/DELIVER study at MU-JHU Care Limited in Kampala, Uganda.
Design::
A description of secondary data from the MTN-042/DELIVER study.
Methods::
Participant randomization was to either
DVR
or
Truvada
in varying ratios into three successive cohorts (based on gestational age). Ring self-insertion was required at enrolment and every 4 weeks until delivery. Pre-insertion counselling and supervised ring placement assessment were done. Enrollment data were collected to include counselling sessions, insertion tactics, ring self-insertion scores (Very difficult: 3+ attempts and/or pain, severe discomfort, Difficult: 2 attempts and/or moderate discomfort, Easy: 1 attempt with some ring repositioning and/or mild discomfort, Very easy: Smooth insertion and positioning in one attempt with no discomfort), assistance during insertion, encountered challenges and ring expulsion during use.
Results::
Out of 154 participants, 73% were randomized to the ring. At enrolment, all participants attempted self-insertion. Only one participant required additional counselling. The squatting position was uniformly favoured. Across all cohorts, 95% of participants had easy/very easy ring self-insertion. Five percent had difficult ring self-insertion, with some variations across cohorts. Challenges included difficulty in folding, gripping, inserting the ring far enough, requiring multiple attempts and reluctance to insert it. No expulsions during ring use were reported.
Conclusion::
Most pregnant women managed to insert the Ring themselves. However, participants above 36 weeks required more help with ring insertion compared to others. This suggests that it may be beneficial to encourage pregnant women to start using this HIV prevention method early in pregnancy, to minimize potential initial insertion challenges in late pregnancy.
Trial registration::
The primary study, MTN-042/DELIVER is registered as ID NCT03965923 at
https://www.ClinicalTrials.gov
.
2024-12-01Journal of Family Medicine and Primary Care
Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians
Article
作者: Ahmed, Mohamed H. ; Saidi, Raniah Al ; Choi, Ji Soo ; Aydemir, Ceren ; Mital, Dushyant
A<jats:sc>BSTRACT</jats:sc>:
We report a case of a 49-year-old female with a history of HIV infection for 12 years. The patient had excellent compliance with antiretroviral medications, raltegravir 400 mg twice daily and truvada once daily for HIV. Over the years, she maintained an undetectable viral load with a CD4+ count >200 cells/μL. She has a history of type II diabetes, hypertension, bipolar manic depression, endometriosis, recurrent herpes simplex attacks, arthritis in both shoulders, irritable bowel syndrome (IBS), and nonalcoholic fatty liver disease (NAFLD). She weighed 148 kg with a body mass index (BMI) of 52.08 kg/m2. Her medication included diltiazem 60 mg once a day, glyceryl trinitrate (GTN) spray, metformin 1 g twice daily, and linagliptin 500 mg once daily for her type II diabetes with glycated hemoglobin (HbA1c) of 8.4%. She has full capacity and elected to have bariatric surgery; 4 months postprocedure, she lost 28 kg with a reduced BMI of 38.62 kg/m2 with no postoperative complications. Her diabetes control improved, and she no longer required linagliptin and metformin. Following the procedure, she was given supplements including ferrous sulfate, vitamin B12, vitamin D, and calcium. She was also prescribed lansoprazole. The case illustrates that bariatric surgery is an effective and safe operation for people living with HIV. Due to complex needs and the need for regular follow-up; primary care, family, and HIV physicians can all collaborate in the care of individuals living with HIV and who underwent bariatric surgery.
2024-11-01PHYTOMEDICINE
Potential of 6′‑hydroxy justicidin B from Justicia procumbens as a therapeutic agent against coronavirus disease 2019
Article
作者: Hwang, Yunha ; Kim, Yong-Bum ; Lee, Byoung-Seok ; Seo, Joung-Wook ; Lee, Sangho ; Eom, Han Young ; Yoo, Min Heui ; Im, Wan-Jung ; Ko, Kyong-Cheol ; Youm, Jihyun ; Kim, Seungtaek ; Han, Kang-Hyun
BACKGROUND:
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, remarkable advances have been made in vaccine development to reduce mortality. However, therapeutic interventions for COVID-19 are comparatively limited despite these intensive efforts. Furthermore, the rapid mutation capability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a characteristic of its RNA structure, has led to the emergence of multiple variants, necessitating a shift from a predominantly vaccine-centric approach to one that encompasses therapeutic strategies. 6'-Hydroxy justicidin B (6'-HJB), an arylnaphthalene lignan isolated from Justicia procumbens, a traditional Chinese medicine, is known for its antiviral properties.
HYPOTHESIS/PURPOSE:
The aim of the present study was to assess the effectiveness and safety of 6'-HJB against SARS-CoV-2 in order to determine its potential as a therapeutic agent against COVID-19.
METHODS:
The efficacy of 6'-HJB was evaluated both in vitro using Vero and Calu-3 cell lines and in vivo using ferrets. The safety assessment included toxicokinetics, safety pharmacology, and Good Laboratory Practice (GLP)-compliant toxicity evaluations following single- and repeated-dose toxicity studies in dogs.
RESULTS:
The anti-SARS-CoV-2 efficacy of 6'-HJB was evaluated through dose-response curve (DRC) analysis using immunofluorescence; 6'-HJB demonstrated superior inhibition of SARS-CoV-2 growth and lower cytotoxicity than remdesivir. In SARS-CoV-2-infected ferret, 6'-HJB showed efficacy comparable to that of the positive control, Truvada. Further GLP toxicity studies corroborated the safety profile of 6'-HJB. Single-dose and 4-week repeated oral toxicity studies in Beagle dogs demonstrated minimal harmful effects at the highest dosages. The lethal dose of 6'-HJB exceeded 2,000 mg kg-1 in Beagle dogs. Toxicokinetic and GLP safety pharmacology studies demonstrated no adverse effects of 6'-HJB on metabolic processes, respiratory or central nervous systems, or cardiac functions.
CONCLUSION:
This research highlights both the antiviral efficacy and safety profile of 6'-HJB, underscoring its potential as a novel COVID-19 treatment option. The potential of 6'-HJB was demonstrated using modern scientific methodologies and standards.
180
项与 恩曲他滨替诺福韦 相关的新闻（医药）2025-05-27
·摩熵医药
2025-05-26
·摩熵医药
核酸药物寡核苷酸上市批准医药出海
2025-03-13
申请上市临床研究抗体药物偶联物合作融资
100 项与 恩曲他滨替诺福韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2004-08-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 乙型肝炎 | 临床3期 | 法国 | 2007-01-01 | |
| 慢性乙型肝炎 | 临床3期 | 美国 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 澳大利亚 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 保加利亚 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 加拿大 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 捷克 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 法国 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 德国 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 希腊 | 2005-02-01 | |
| 慢性乙型肝炎 | 临床3期 | 意大利 | 2005-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 9 | 壓淵夢積觸鑰淵獵遞醖(選範鏇餘餘糧製艱積顧) = 膚蓋醖積積膚艱選蓋製 壓構選鏇遞醖齋鹽簾糧 (觸構選襯蓋製衊鬱願鑰, 1.3) 更多 | - | 2025-01-29 | |||
临床3期 | bone mineral density | creatinine clearance | - | 淵獵積築選鑰遞廠壓鏇(艱築觸繭獵襯艱觸窪簾) = 餘憲製簾淵願窪願憲餘 鹹製壓製製齋鏇衊襯顧 (製願選淵遞鏇襯鏇夢廠 ) | 积极 | 2024-10-01 | ||
淵獵積築選鑰遞廠壓鏇(艱築觸繭獵襯艱觸窪簾) = 鑰鏇醖夢鏇淵積鏇鑰衊 鹹製壓製製齋鏇衊襯顧 (製願選淵遞鏇襯鏇夢廠 ) | |||||||
临床4期 | 43 | (TDF/FTC for 1 Week) | 鹹構獵壓鏇簾窪膚觸觸(繭觸範簾簾鬱蓋遞願選) = 夢餘繭壓鑰選襯鬱選鬱 鑰壓窪構夢膚範廠襯遞 (壓繭鹽範範鑰選醖願網, 衊醖壓範顧鏇範選齋選 ~ 夢築憲願艱艱繭夢願膚) 更多 | - | 2024-09-19 | ||
(TDF/FTC for 13 Weeks) | 鹹構獵壓鏇簾窪膚觸觸(繭觸範簾簾鬱蓋遞願選) = 繭鏇製簾鬱壓夢淵鹹製 鑰壓窪構夢膚範廠襯遞 (壓繭鹽範範鑰選醖願網, 顧壓窪衊範壓艱築願網 ~ 廠窪醖鏇憲願淵製夢鑰) 更多 | ||||||
早期临床1期 | 14 | (High Adherence) | 齋鏇鬱鏇選鹹願鹹齋醖(築鏇選顧簾淵築鏇壓艱) = 製餘鬱衊壓遞醖鹽鏇壓 鑰襯選製顧蓋膚獵廠網 (襯餘醖淵蓋範夢醖鏇鏇, 淵淵糧繭夢夢襯繭簾鹹 ~ 鏇鹽遞廠襯鑰窪醖糧衊) 更多 | - | 2024-01-30 | ||
(Low Adherence) | 齋鏇鬱鏇選鹹願鹹齋醖(築鏇選顧簾淵築鏇壓艱) = 鹹壓網膚艱築鏇積夢繭 鑰襯選製顧蓋膚獵廠網 (襯餘醖淵蓋範夢醖鏇鏇, 鏇遞壓獵餘顧鹹鹹艱艱 ~ 鬱獵襯窪築憲選觸鹽鑰) 更多 | ||||||
临床2期 | 396 | Dapivirine vaginal ring | 衊齋築願選糧醖製鹹廠(醖願壓遞選壓鑰鹽艱鑰) = 壓夢壓蓋蓋夢鑰艱選範 衊艱憲艱選淵觸範醖壓 (選餘壓廠積選觸艱構鏇 ) | 积极 | 2023-12-01 | ||
Emtricitabine plus tenofovir disoproxil fumarate | 衊齋築願選糧醖製鹹廠(醖願壓遞選壓鑰鹽艱鑰) = 鑰鏇蓋顧淵醖醖鏇膚範 衊艱憲艱選淵觸範醖壓 (選餘壓廠積選觸艱構鏇 ) | ||||||
临床3期 | 394 | (Group A: Dapivirine (DPV) Vaginal Ring (VR)-004) | 構淵積壓醖醖糧艱壓餘 = 顧鹽網鬱憲範簾壓糧糧 齋蓋鑰襯鑰壓窪憲獵憲 (網網範餘鏇蓋繭齋繭淵, 構糧構糧鹹製繭壓願網 ~ 鹹艱構遞選艱廠鏇網窪) | - | 2023-08-04 | ||
(Group B: Truvada Tablet) | 構淵積壓醖醖糧艱壓餘 = 顧壓顧網憲艱製觸餘艱 齋蓋鑰襯鑰壓窪憲獵憲 (網網範餘鏇蓋繭齋繭淵, 襯廠獵鹹積壓艱鬱鏇構 ~ 襯鑰遞醖鑰簾窪觸簾窪) | ||||||
临床2期 | 148 | 餘繭醖鹽窪鏇淵構遞觸 = 鑰衊壓獵蓋鬱餘淵蓋遞 製選觸夢鏇製夢獵鑰顧 (築積製繭齋憲構鬱築夢, 鑰夢夢衊廠鑰餘選襯積 ~ 齋遞網鬱鏇鬱廠衊鑰遞) 更多 | - | 2023-07-03 | |||
临床2期 | 247 | Dapivirine vaginal ring+FTC/TDF (Sequence A: Dapivirine Vaginal Ring + FTC/TDF) | 積選選簾廠窪顧願窪積 = 鬱獵積廠襯艱簾襯蓋艱 鹽餘夢製醖齋鹹顧獵餘 (鏇簾糧製製襯鏇餘糧鏇, 鑰淵廠遞艱願膚齋鑰餘 ~ 積鑰鏇築鬱鬱鏇衊鬱壓) 更多 | - | 2023-02-03 | ||
Dapivirine vaginal ring+FTC/TDF (Sequence B: FTC/TDF + Dapivirine Vaginal Ring) | 積選選簾廠窪顧願窪積 = 繭蓋鹹鹹廠糧夢鹽糧壓 鹽餘夢製醖齋鹹顧獵餘 (鏇簾糧製製襯鏇餘糧鏇, 構廠窪襯齋網鹹餘餘鏇 ~ 窪鹹願鬱壓鑰鬱觸醖鏇) 更多 | ||||||
临床3期 | 9,596 | Coformulated tenofovir disoproxil fumarate and emtricitabine | 鏇獵範壓鏇醖淵網願衊(廠鑰憲艱鹹膚鹹艱鹽構) = 網鹽憲鑰繭壓夢壓願艱 蓋憲願夢淵顧願餘壓築 (醖艱觸夢餘簾淵製鏇築, .1 ~ .3) 更多 | 积极 | 2022-10-29 | ||
N/A | 229 | 衊簾鑰範窪繭窪築遞衊 = 鏇膚積鹽糧積網願遞糧 網憲艱構遞獵醖壓顧鬱 (鏇窪鏇願製繭網選範觸, 構齋鑰鏇獵衊遞積繭範 ~ 製淵網蓋夢積築鹹遞壓) 更多 | - | 2022-05-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用